Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.
Article By Kelsy Ketchum / July 12, 2022
Would you like to learn more about working with Outcome Capital or discuss your specific needs?